These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 10967805)
1. Clinical data released on ABT-378/r. AIDS Read; 2000 Aug; 10(8):468. PubMed ID: 10967805 [No Abstract] [Full Text] [Related]
2. [Results of a large randomized study: after switch to LPV/r quality of life improved]. MMW Fortschr Med; 2003 Apr; 145 Spec No 1():49. PubMed ID: 15011589 [No Abstract] [Full Text] [Related]
3. [Justified hope after 4 years. Initial therapy still without resistance]. MMW Fortschr Med; 2003 Apr; 145 Spec No 1():48-9. PubMed ID: 15011588 [No Abstract] [Full Text] [Related]
4. ["Double boosting" passes the test. LPV/r plus SQV in complicated salvage situation]. MMW Fortschr Med; 2003 Apr; 145 Spec No 1():85. PubMed ID: 15011607 [No Abstract] [Full Text] [Related]
5. [Overcoming weaknesses in therapy. Protease inhibitors with high IQ]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():96-7. PubMed ID: 11373795 [No Abstract] [Full Text] [Related]
10. Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy". Sax PE AIDS Clin Care; 2005 Jan; 17(1):4. PubMed ID: 15717366 [No Abstract] [Full Text] [Related]
11. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation. Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839 [TBL] [Abstract][Full Text] [Related]
12. Changes in Kaletra labelling. AIDS Patient Care STDS; 2004 Mar; 18(3):181-2. PubMed ID: 15116435 [No Abstract] [Full Text] [Related]
14. FDA notifications. Generic lopinavir/ritonavir approved by FDA. AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652 [No Abstract] [Full Text] [Related]
15. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262 [TBL] [Abstract][Full Text] [Related]
16. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055 [No Abstract] [Full Text] [Related]